Browse studies

Find your next paid study

27,332 recruiting studies available now

GF-NOURISH (Gluten Free Nutrition Optimization Through Ultra-processed Food Reduction and Improved Strategies for Health)

The investigators propose the Gluten Free Nutrition Optimization through Ultra-processed food Reduction and Improved Strategies for Health (GF-NOURISH) study t…

Celiac Disease in ChildrenNutrition Disorder, Child

Estimated

~$10 – $750

Actual pay is set by the research site.

Boston Children's HospitalNCT06356220

Phase 3

A Phase III, Multisite, Randomized, Double-Blind Trial of BNT327 in Combination With Chemotherapy Versus Placebo With Chemotherapy in Patients With Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC Determined Ineligible for PD(L)1 Therapy Based on PD-L1 Negative Disease

This is a Phase III trial where participants will be randomized to two treatment groups, which means participants will be assigned by equal chance to a treatme…

Breast Neoplasms

Estimated

~$50 – $2,250

Actual pay is set by the research site.

BioNTech SENCT07173751

Phase 2

A Randomized, Double-Blind, Placebo-Controlled Mechanistic Study to Assess a Single Oral Dose of CYB003 in Participants With Major Depressive Disorder (MDD) and Moderate to Severe Anxiety

The goal of this study is to learn how psychedelics may help symptoms of depression and anxiety. Participants with major depressive disorder experiencing sympt…

DepressionAnxietyMajor Depressive Disorder

Estimated

~$75 – $2,000

Actual pay is set by the research site.

Ohio State UniversityNCT06820723

Phase 3

A Long-Term Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Multiple Maintenance Doses of Oral Once Daily Aleniglipron for Chronic Weight Management in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)

This is randomized, double-blind, placebo-controlled study of the long-term efficacy, safety, and tolerability of multiple doses of aleniglipron in participant…

ObesityOverweightChronic Weight Management+1 more

Estimated

~$50 – $2,100

Actual pay is set by the research site.

Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure TherapeuticsNCT07654374

Wearable Sensor Platform to Monitor Stroke Recovery During Inpatient Rehabilitation

This observational trial seeks to assess the feasibility of using non-invasive, portable, real-time body-worn sensors to continuously monitor, quantify, and in…

Stroke

Estimated

~$10 – $1,125

Actual pay is set by the research site.

Shirley Ryan AbilityLabNCT04219670

Phase 1

Phase 1, Open Label, Dose Escalation Study to Evaluate the Safety, Expansion, Persistence, and Preliminary Clinical Activity of Autologous CD64 CAR T Cells in Patients With Relapsed and/or Refractory Acute Myeloid Leukemia (AML)

This is a Phase 1, open label, dose-escalation study to evaluate the safety, expansion, persistence, and preliminary clinical activity of lentivirally transduc…

Refractory Acute Myeloid Leukemia (AML)Relapsed Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome+1 more

Estimated

~$150 – $3,000

Actual pay is set by the research site.

University of Colorado, DenverNCT07347418

Phase 1

Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cell Exosome Intranasal Instillations for the Treatment of Stroke

This trial will study the safety and efficacy of intranasal instillation of cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cell…

Stroke

Estimated

~$150 – $3,000

Actual pay is set by the research site.

The Foundation for Orthopaedics and Regenerative MedicineNCT05158101

Observational

The Cardiometabolic Impact of Non-Nutritive Sweeteners in Young Adults With Type 1 Diabetes

This project will apply a novel non-nutritive sweetener (NNS) dietary assessment tool with measurement of circulating NNS levels in a pediatric population, all…

Non-Nutritive SweetenerType 1 Diabetestype1diabetes+1 more

Estimated

~$10 – $750

Actual pay is set by the research site.

Medical College of WisconsinNCT07434544

Phase 2

A Phase 2/3, Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Oral Ozanimod (RPC1063) in Pediatric Subjects With Moderately to Severely Active Ulcerative Colitis With an Inadequate Response to Conventional Therapy

The purpose of this study is to evaluate the effectiveness and safety of ozanimod (RPC1063) in achieving and maintaining clinical remission. Ozanimod will be a…

Colitis, Ulcerative

Estimated

~$75 – $3,000

Actual pay is set by the research site.

Bristol-Myers SquibbNCT05076175

Phase 3

A Phase 3, Randomized, Double-mask, Placebo-controlled Study With Open-label Extension to Evaluate the Efficacy and Safety of Linsitinib in Participants With Moderate to Severe Active Thyroid Eye Disease (TED)

The goal of this clinical trial is to evaluate the efficacy, safety, and tolerability of linsitinib in participants with moderate to severe Thyroid Eye Disease…

Thyroid Eye Disease, TEDGraves Orbitopathy

Estimated

~$50 – $2,100

Actual pay is set by the research site.

Sling Therapeutics, Inc.NCT07753603

Phase 3

A Phase IIIb, Single-Arm, Open-Label Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes (PRO) of Giredestrant in Patients With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy

The purpose of this study is to understand treatment adherence and patient-reported outcomes of switching to giredestrant due to prior aromatase inhibitor (AI)…

Early Breast Cancer

Estimated

~$50 – $2,100

Actual pay is set by the research site.

Genentech, Inc.NCT07541079

Phase 3

Phase III Study of Ginseng for Cancer Related Fatigue

This phase III trial compares the effect of Wisconsin ginseng (panax quinquefolius) to placebo in patients with cancer that suffer from significant fatigue. Fa…

Malignant Solid NeoplasmChronic Lymphocytic LeukemiaHematopoietic and Lymphatic System Neoplasm+3 more

Estimated

~$50 – $1,500

Actual pay is set by the research site.

Mayo ClinicNCT06395441